Merger Update: Dechra / Elanco

Start of CMA Merger Investigation: anticipated acquisition by Dechra Pharmaceuticals PLC of the Osurnia business of Elanco Animal Health Incorporated

The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services. 

The CMA announced the launch of its merger inquiry by notice to the Parties on 20 April 2020 and has a deadline of 17 June 2020 for its phase 1 decision.